After nearly a decade of debate, the South African government has issued a new intellectual property policy that was greeted with enthusiasm by patient advocates, who maintained the directive will greatly widen access to medicines.
The policy, which must still be crafted into legislation and then enacted into law, would allow more rigorous patent reviews, introduce procedures for allowing challenges to patent decisions, and define the grounds and procedures for issuing compulsory licenses, among other things.
About the Author Reprints
